5 Stocks Poised for Breakouts: Trulia and More
at The Street - Fri Dec 12, 11:36AM CST
These are the stocks that often go on to make monster moves to the upside.
TILE: 15.92 (+0.17), OGXI: 2.30 (-0.04), MOBL: 9.07 (+0.09), TRLA: 50.63 (+0.29), MCHX: 4.02 (-0.01)
OncoGenex: Deep Pipeline For Microcap Offers Significant Upside
Daniel Ward - at Seeking Alpha - Wed Dec 10, 9:11AM CST
OGXI: 2.30 (-0.04)
OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
CNW Group - Mon Nov 17, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 10:55 a.m. ET at the New York Palace Hotel in New York City. The presentation will include an overview of apatorsen Phase 2 development plans, as well as additional data from custirsen Phase 3 SYNERGY exploratory analyses.
OGXI: 2.30 (-0.04)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 344.49 (+2.16), ALNY: 100.45 (+0.23), ISIS: 62.32 (+0.45), OGXI: 2.30 (-0.04), TEVA: 55.92 (-0.92), RGLS: 16.06 (-0.25), GSK: 42.42 (-0.93), SNY: 45.16 (-1.05)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.87 (+0.27), PCYC: 132.65 (-2.34), CLDX: 18.03 (-0.16), INCY: 74.65 (-1.27), BIND: 5.82 (+0.02), CELG: 114.49 (-2.25), OMER: 22.81 (+0.12), VSTM: 8.99 (-0.04), GILD: 104.13 (-0.18), OGXI: 2.30 (-0.04), ANTH: 2.05 (+0.08), NVAX: 5.76 (-0.17)
OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 3:04AM CST
OGXI: 2.30 (-0.04)
More on OncoGenex Pharmaceuticals Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:32PM CDT
OGXI: 2.30 (-0.04)
OncoGenex Pharmaceuticals beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT
OGXI: 2.30 (-0.04)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.30 (-0.04), TEVA: 55.92 (-0.92)
Some Of Soros' Stocks Surged Today, While Others Soured
at The Street - Wed Oct 29, 3:31PM CDT
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), MCG Capital Corp (NASDAQ:MCGC) and Doral Financial Corp. (NYSE
OGXI: 2.30 (-0.04), MCGC: 3.66 (+0.08), INVN: 15.18 (-0.29), DRL: 3.75 (+0.20), ARCP: 8.99 (-0.24)
OncoGenex reports on October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:27AM CDT
OGXI: 2.30 (-0.04)
OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014
PR Newswire - Thu Oct 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OGXI: 2.30 (-0.04)
OncoGenex's Phase III Prostate Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:11PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) has finished enrolling patients in a phase III study (AFFINITY) on custirsen for metastatic castrate-resistant prostate cancer.
LCI: 43.58 (-0.46), ENDP: 68.77 (-2.45), OGXI: 2.30 (-0.04), TEVA: 55.92 (-0.92)
5 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Sep 18, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
NLST: 0.65 (-0.03), ANY: 6.14 (+0.19), OGXI: 2.30 (-0.04), GLYC: 9.00 (+0.49)
OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer
PR Newswire - Tue Sep 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Phase 3 AFFINITY trial.
OGXI: 2.30 (-0.04), TEVA: 55.92 (-0.92)
4 Under-$10 Biotech Stocks in Breakout Territory
at The Street - Wed Aug 27, 6:00AM CDT
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.
OGXI: 2.30 (-0.04), ARTX: 2.25 (+0.01), CYTR: 2.29 (+0.05), CNCE: 11.22 (+0.03)